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DEAR EDITOR, The high prevalence and physical, psychological
and economic burden of chronic skin conditions emphasize the
need for cost-effective multidisciplinary treatment options.1 Cog-
nitive behavioural therapy (CBT) reduces physical and psycho-
logical symptoms in chronic skin conditions,2 and is increasingly
offered online.3 However, cost-effectiveness studies of internet-
based CBT (ICBT) for chronic skin conditions are lacking. In our
previous randomized controlled trial (RCT), individually tai-
lored, therapist-guided ICBT improved physical functioning and
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decreased disease impact in patients with psoriasis.4 The current
study examines the cost-effectiveness of this intervention.
This economic evaluation from a societal perspective was
conducted alongside an open-label parallel-group RCT com-
paring the effects of care as usual (CAU; regular dermato-
logical care) with additional ICBT aimed at reducing the
impact of psoriasis on daily life (ICBT+CAU) in 131
patients with psoriasis. Methodological details are described
elsewhere.4 The ICBT focused on itch, pain, fatigue, nega-
tive mood and social relationships. Costs (self-reported
health care and medication use, patient travel costs, loss of
productivity costs in paid labour and ICBT costs4) and
effects [quality-adjusted life years (QALYs)4] were assessed
at baseline, post-treatment and 6-month follow-up. Baseline
between-group cost differences were analysed with indepen-
dent-samples t-tests. An incremental cost–utility ratio (ICUR)
was calculated by dividing between-group cost differences
by the QALY differences for the 12-month study period.
Uncertainty surrounding the ICUR was based on boot-
strapped samples (1000 replications).
No baseline between-group differences in sociodemographic
and disease-related characteristics, and outcomes were found
(P-values ≥ 010), except for a higher clinician-rated disease
severity in the ICBT+CAU group (P = 003). The primary cost–
utility analysis showed no between-group differences in effects
(average QALY ICBT+CAU vs. CAU 079 vs. 078; mean QALY
difference –0014; 25–975 percentile –0062 to 0038) or
costs (average costs ICBT+CAU vs. CAU €6641 vs. €5346; mean
difference €1295; 25–975 percentile –€1502 to €4176) at
post-treatment and 6-months follow-up (P ≥ 045). The north-
west quadrant of the cost-effectiveness plane (Fig. 1a) con-
tained the majority of ICURs (58%), suggesting larger societal
costs and QALY losses after ICBT+CAU than CAU alone. Greater
QALY improvements in the ICBT+CAU group, but at higher
societal costs (northeast quadrant), had a 24% probability.
Although the intervention was aimed at patients with moder-
ate-to-high disease burden, the sample had relatively low disease
burden.4 To examine the impact of disease burden, four post
hoc subgroup analyses were performed on patients with high vs.
low (median split) baseline scores on (i) self-assessed disease
severity; (ii) clinician-assessed disease severity; (iii) psychologi-
cal distress; and (iv) self-perceived disease impact. For patients
with high self-reported disease severity and high self-reported
disease impact, ICBT+CAU was generally associated with greater
effects at lower societal costs than CAU (i.e. 60% and 78% ICURs
in the southeast quadrant, respectively, compared with 0% and
0% in low-scoring patients; Fig. 1b–e). The probability that
ICBT is cost-effective for patients with high self-reported disease
severity and impact at a willingness to pay of €20 000 per QALY
gained5 is 78% (mean ICUR –55978; mean cost reduction –€
593; mean QALY increase 005) and 95% (mean ICUR –94371;
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Fig 1. Cost-effectiveness planes for main cost-effectiveness analysis (a), and subgroups of high (b) vs. low (c) self-assessed disease severity, and
high (d) vs. low (e) self-assessed disease impact. WTP, willingness to pay.
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respectively. In contrast, for patients with high clinician-assessed
disease severity and high psychological distress, ICBT+CAU was
generally associated with lower effects at higher costs than CAU
(86% and 78% of ICURs in the northwest quadrant, respectively,
compared with 31% and 4% in low-scoring patients).
That ICBT+CAU was not cost-effective compared with CAU in
the total group may be explained by between-group imbalance
[i.e. higher disease severity and descriptively higher baseline
costs, systemic medication use and greater labour market partici-
pation (more possible productivity losses) in the ICBT+CAU
group]. Moreover, the generic effect measure (EQ-5D) may not
be specific enough to detect health-related quality of life
(HRQoL) aspects in dermatological samples,6 combined with
limited responsiveness and ceiling effects across conditions.7,8
The finding that ICBT+CAU was cost-effective for patients
with high self-reported disease severity and impact clearly sug-
gests the target audience of this intervention. As societal costs
were lower in the ICBT+CAU than CAU group at 6-month fol-
low-up, the intervention may be cost-effective even when soci-
ety is not willing to pay anything for it. However, follow-up
trials including patients with higher disease burden are needed
to corroborate these findings. Strengths of this study include
the RCT design, outpatient sample and analysis of direct and
indirect costs. Including a sensitive-to-change dermatology-spe-
cific HRQoL measure might aid the assessment of clinically rele-
vant improvement in future cost-effectiveness studies.
In conclusion, although ICBT was not considered cost-effec-
tive in comparison with CAU in the overall sample, subgroup
analyses suggested cost-effectiveness for patients who experience
high self-assessed disease severity and impact. Screening for these
characteristics, and offering ICBT specifically to patients with ele-
vated levels, may be cost-effective and clinically relevant.
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